Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy
- PMID: 21302287
- PMCID: PMC3229838
- DOI: 10.1002/jcp.22636
Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Fourteen sarcomeric and sarcomere-related genes have been implicated in HCM etiology, those encoding β-myosin heavy chain (MYH7) and cardiac myosin binding protein C (MYBPC3) reported as the most frequently mutated: in fact, these account for around 50% of all cases related to sarcomeric gene mutations, which are collectively responsible for approximately 70% of all HCM cases. Here, we used denaturing high-performance liquid chromatography followed by bidirectional sequencing to screen the coding regions of MYH7 and MYBPC3 in a cohort (n = 125) of Italian patients presenting with HCM. We found 6 MHY7 mutations in 9/125 patients and 18 MYBPC3 mutations in 19/125 patients. Of the three novel MYH7 mutations found, two were missense, and one was a silent mutation; of the eight novel MYBPC3 mutations, one was a substitution, three were stop codons, and four were missense mutations. Thus, our cohort of Italian HCM patients did not harbor the high frequency of mutations usually found in MYH7 and MYBPC3. This finding, coupled to the clinical diversity of our cohort, emphasizes the complexity of HCM and the need for more inclusive investigative approaches in order to fully understand the pathogenesis of this disease.
Copyright © 2011 Wiley-Liss, Inc.
Figures


Similar articles
-
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.J Cardiovasc Med (Hagerstown). 2006 Aug;7(8):601-7. doi: 10.2459/01.JCM.0000237908.26377.d6. J Cardiovasc Med (Hagerstown). 2006. PMID: 16858239
-
Prevalence and Phenotypic Expression of Mutations in the MYH7, MYBPC3 and TNNT2 Genes in Families with Hypertrophic Cardiomyopathy in the South of Brazil: A Cross-Sectional Study.Arq Bras Cardiol. 2016 Sep;107(3):257-265. doi: 10.5935/abc.20160133. Arq Bras Cardiol. 2016. PMID: 27737317 Free PMC article.
-
Spectrum of Mutations in Hypertrophic Cardiomyopathy Genes Among Tunisian Patients.Genet Test Mol Biomarkers. 2016 Nov;20(11):674-679. doi: 10.1089/gtmb.2016.0187. Epub 2016 Aug 30. Genet Test Mol Biomarkers. 2016. PMID: 27574918
-
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24. Clin Res Cardiol. 2018. PMID: 28840316 Review.
-
Long-Term Prevalence of Systolic Dysfunction in MYBPC3 Versus MYH7-Related Hypertrophic Cardiomyopathy.Circ Genom Precis Med. 2023 Aug;16(4):363-371. doi: 10.1161/CIRCGEN.122.003832. Epub 2023 Jul 6. Circ Genom Precis Med. 2023. PMID: 37409452 Review.
Cited by
-
Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program.J Cardiovasc Transl Res. 2013 Feb;6(1):65-80. doi: 10.1007/s12265-012-9425-0. Epub 2012 Dec 12. J Cardiovasc Transl Res. 2013. PMID: 23233322 Free PMC article.
-
A low prevalence of MYH7/MYBPC3 mutations among familial hypertrophic cardiomyopathy patients in India.Mol Cell Biochem. 2012 Jan;360(1-2):373-82. doi: 10.1007/s11010-011-1077-x. Epub 2011 Sep 29. Mol Cell Biochem. 2012. PMID: 21959974
-
Poor prognosis of rare sarcomeric gene variants in patients with dilated cardiomyopathy.Clin Transl Sci. 2013 Dec;6(6):424-8. doi: 10.1111/cts.12116. Epub 2013 Oct 3. Clin Transl Sci. 2013. PMID: 24119082 Free PMC article.
-
MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients.Orphanet J Rare Dis. 2016 Jul 7;11(1):91. doi: 10.1186/s13023-016-0476-1. Orphanet J Rare Dis. 2016. PMID: 27387980 Free PMC article.
-
Application of Long-Read Nanopore Sequencing to the Search for Mutations in Hypertrophic Cardiomyopathy.Int J Mol Sci. 2022 Dec 13;23(24):15845. doi: 10.3390/ijms232415845. Int J Mol Sci. 2022. PMID: 36555486 Free PMC article.
References
-
- Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics. J Cardiovasc Electrophysiol. 2008;19:104–110. - PubMed
-
- Alders M, Jongbloed R, Deelen W, van den Wijngaard A, Doevendans P, Ten Cate F, Regitz-Zagrosek V, Vosberg HP, van Langen I, Wilde A, Dooijes D, Mannens M. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848–1853. - PubMed
-
- Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45:1076–1080. - PubMed
-
- Bordoni R, Bonnal R, Rizzi E, Carrera P, Benedetti S, Cremonesi L, Stenirri S, Colombo A, Montrasio C, Bonalumi S, Albertini A, Bernardi LR, Ferrari M, De Bellis G. Evaluation of human gene variant detection in amplicon pools by the GS-FLX parallel Pyrosequencer. BMC Genomics. 2008;9:464. - PMC - PubMed
-
- Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:201–211. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources